Fortitude Family Office’s KalVista Pharmaceuticals KALV Stock Holding History

Fortitude Family Office’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-94	Closed	-$1.89K	–	2326
2026 Q1	$1.89K	Buy	94 +34	+57%	+$548	﹤0.01%	1303
2025 Q4	$969	Buy	+60	New	+$795	﹤0.01%	1468
2024 Q4	–	Sell	-3	Closed	-$35	–	1350
2024 Q3	$35	Hold	3	–	–	﹤0.01%	1203
2024 Q2	$35	Hold	3	–	–	﹤0.01%	959
2024 Q1	$36	Hold	3	–	–	﹤0.01%	966
2023 Q4	$37	Buy	+3	New	+$27	﹤0.01%	1004

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fortitude Family Office's KALV Position: Q2 2026 in Review

Fortitude Family Office sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 94 shares — an estimated $1.89K sold.

Fortitude Family Office first reported a position in KALV in Q4 2023 and held it in 6 quarters. The position peaked at $1.89K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Fortitude Family Office reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Fortitude Family Office sold 94 KalVista Pharmaceuticals shares in Q2 2026, an estimated $1.89K.
Fortitude Family Office first reported a position in KalVista Pharmaceuticals in Q4 2023 and held it in 6 quarters.
Fortitude Family Office's KalVista Pharmaceuticals position peaked at $1.89K in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.